Scientific deep-dive

What Is Orforglipron (Foundayo)? Mechanism, Maker & Pronunciation

Orforglipron (Foundayo) is Eli Lilly's once-daily oral GLP-1, the first non-peptide GLP-1 approved for weight loss, cleared by the FDA on April 1, 2026. Being a small molecule is why it can be a pill. How it works, ATTAIN-1 results, and how to pronounce it.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10 min read·11 citations

Orforglipron is the first small-molecule (non-peptide) oral GLP-1 pill approved for weight loss. Its US brand name is Foundayo, it is made by Eli Lilly and Company, and the FDA approved it on April 1, 2026 for chronic weight management in adults with obesity or overweight with a weight-related medical condition[1][2]. This article is the foundational explainer: what orforglipron is as a drug, who makes it, how the small-molecule GLP-1 mechanism works, what it is approved for, how effective it is in trials, what it costs, and how to pronounce the name.

Quick answer

Orforglipron is a once-daily oral GLP-1 receptor agonist tablet, sold in the US under the brand name Foundayo, made by Eli Lilly, FDA-approved on April 1, 2026 for chronic weight management. It is the first non-peptide, small-molecule GLP-1 ever approved — which is the chemistry reason it can be a pill instead of an injection. Mean weight loss at the labeled 17.2 mg dose was about 11.1% over 72 weeks in the ATTAIN-1 phase 3 trial[1]. The Foundayo Savings Card brings eligible commercially insured patients to as low as $25/month, and self-pay through LillyDirect starts at $149/month for the lowest doses[4].

Compare vetted GLP-1 providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Starting price: $149/mo (+ required membership)

Get started →Read review Ro →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →

What is orforglipron?

Orforglipron is the generic (international nonproprietary) name for a prescription weight-management drug developed by Eli Lilly and Company. In the US it is sold under the brand name Foundayo[1]. The drug was originally discovered by Chugai Pharmaceutical and licensed to Eli Lilly, and Lilly developed it through phase 1, 2, and 3 trials under the internal designation LY3502970[2].

Pharmacologically, orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist[1]. Translated into plain language: it binds and activates the same receptor (the glucagon-like peptide-1 receptor) that semaglutide, tirzepatide, liraglutide, and every other GLP-1 weight-loss drug binds and activates — but unlike those drugs, it is not a peptide. That single chemistry distinction is the reason orforglipron can be taken as a swallowable tablet rather than as an injection. We unpack that mechanism in detail below.

Foundayo is supplied as a once-daily oral tablet in six labeled strengths — 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg (the labeled maximum) — taken at any time of day with or without food, and with no water restrictions[1]. The half-life per the FDA prescribing information is 29-49 hours, much shorter than injectable semaglutide (~7 days) or injectable tirzepatide (~5 days), which is why it is dosed once daily instead of once weekly[1].

One important labeled drug-drug interaction: when co-administered with a strong CYP3A4 inhibitor (e.g., clarithromycin, itraconazole, or ketoconazole), the maximum labeled Foundayo dose is reduced to 9 mg once daily[1]. Strong CYP3A4 inhibitors that also inhibit OATP1B, such as ritonavir, should be avoided altogether rather than dose-capped. Strong CYP3A4 inhibitors raise orforglipron exposure meaningfully, which is why the label caps or avoids them.

Who makes orforglipron?

Orforglipron is manufactured and marketed by Eli Lilly and Company, the Indianapolis-based pharmaceutical company that also makes Mounjaro and Zepbound (the brand names for tirzepatide, the injectable dual GIP/GLP-1 agonist FDA-approved for type 2 diabetes and chronic weight management, respectively)[2]. Lilly is one of the two companies that effectively created the modern incretin weight-loss market — the other being Novo Nordisk, which makes semaglutide (Ozempic, Wegovy, Rybelsus).

Lilly's strategic rationale for developing an oral small-molecule GLP-1 is straightforward. Injectable GLP-1 drugs are extraordinarily effective but the manufacturing is constrained: peptide synthesis is slow, expensive, and requires sterile injectable formulation. A small-molecule oral drug is dramatically cheaper to manufacture, can be scaled the way an ordinary tablet is scaled, and removes the needle-phobia barrier that keeps a meaningful fraction of eligible patients off the injectable GLP-1 class entirely. Lilly has publicly stated that orforglipron was engineered specifically to be the GLP-1 that closes those gaps[2].

How does orforglipron work?

Orforglipron is a GLP-1 receptor agonist, which means it activates the same receptor that the body's own glucagon-like peptide-1 hormone activates after a meal. The downstream effects of GLP-1 receptor activation are well characterized[1]:

  • Appetite suppression. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signaling and reward-driven eating, so patients feel less hungry between meals and are satisfied with smaller portions.
  • Slowed gastric emptying. GLP-1 activation slows the rate at which the stomach passes food into the small intestine, which prolongs the feeling of fullness after a meal.
  • Increased satiety. The combined central and peripheral effects produce earlier and longer-lasting satiety, which is what drives the sustained calorie deficit that produces the trial-reported weight loss.
  • Glucose-dependent insulin secretion. GLP-1 stimulates insulin release from pancreatic beta cells when blood glucose is elevated, which is why GLP-1 drugs are also used for type 2 diabetes (orforglipron is being studied separately in diabetes under the ACHIEVE program).

The chemistry detail that matters: every other FDA-approved GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide) is a peptide — a short chain of amino acids. Peptides are digested in the stomach, which is why all of them need to be injected to survive into the bloodstream. The partial exceptions are oral semaglutide tablets: Rybelsus (oral semaglutide for type 2 diabetes) and the Wegovy tablet for weight management. Both are peptide semaglutide formulated with an absorption enhancer, and the Wegovy tablet label says to take it on an empty stomach with up to 4 ounces of water and wait at least 30 minutes before eating, drinking, or taking other oral medications[11].

Orforglipron is not a peptide at all. It is a small organic molecule designed from the ground up to bind the GLP-1 receptor. Because it is a small molecule, it survives stomach acid and the digestive enzymes that destroy peptides, it does not require an absorption enhancer, and the label says to take it with or without food[1]. That is the reason it works as an ordinary swallowable tablet — and the reason it is the first small-molecule oral GLP-1 approved for weight loss.

What is orforglipron used for?

The FDA-approved indication for Foundayo is to reduce excess body weight and maintain weight reduction long term in either of these adult groups[1]:

  • Adults with obesity, or
  • Adults with overweight plus at least one weight-related comorbid condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

The label does not state BMI cutoffs. The ATTAIN-1 trial behind it enrolled adults with a BMI of 30 kg/m² or higher, or 27 to under 30 kg/m² with at least one weight-related condition[1].

Foundayo is intended to be used as an adjunct to a reduced-calorie diet and increased physical activity, the same wraparound prescribing language that appears on every FDA-approved chronic weight management drug[1].

Orforglipron is also being investigated for type 2 diabetes (the ACHIEVE program), obstructive sleep apnea, knee osteoarthritis, hypertension, and several other indications, but as of November 2026 the only FDA-approved use is the chronic weight management indication described above[2]. For the full ATTAIN-1 trial breakdown and efficacy estimands, see our Foundayo FDA approval deep-dive.

How is it different from other GLP-1s?

The simplest framing is the form-vs-effect-size trade-off. Foundayo is the first small-molecule oral option in the GLP-1 weight-loss class. The injectables produce more weight loss on average, but require a needle. Here is how the four major GLP-1 weight-loss drugs compare on the dimensions patients actually care about:

DrugFormFrequencyHalf-lifeMean weight lossFDA year
Foundayo (orforglipron)Oral tabletDaily29-49 hours~11.1% (17.2 mg)2026
Wegovy (semaglutide)InjectionWeekly~7 days~14.9% (2.4 mg)2021
Zepbound (tirzepatide)InjectionWeekly~5 days~20.9% (15 mg)2023
Saxenda (liraglutide)InjectionDaily~13 hours~8.0% (3 mg)2014

For a head-to-head walkthrough that includes pricing, side-effect profile, and the case for choosing each drug, see our Foundayo vs Wegovy vs Zepbound comparison.

How effective is orforglipron?

Foundayo's approval was anchored on the ATTAIN-1 phase 3 trial, a 72-week randomized, double-blind, placebo-controlled trial in 3,127 adults with obesity or overweight without type 2 diabetes (adults with type 2 diabetes were studied separately in ATTAIN-2 and the ACHIEVE program)[3]. The FDA-labeled mean weight loss at the labeled maximum 17.2 mg dose was approximately 11.1% (roughly 25 pounds from the trial's average starting weight of about 227 pounds) over 72 weeks in the non-diabetic population per the Foundayo prescribing information[1].

Honest framing: Foundayo's effect size sits below injectable semaglutide and well below tirzepatide. STEP-1 reported about 14.9% mean weight loss for Wegovy 2.4 mg weekly[7], and SURMOUNT-1 reported about 20.9% for Zepbound 15 mg weekly[8]. The trade-off Foundayo offers patients is roughly 3-10 percentage points less weight loss in exchange for a daily pill that requires no needles, no cold-chain shipping, and no sharps disposal. For patients who would not otherwise start a GLP-1 because of injection burden, that trade-off is the entire point of the drug.

Magnitude comparison

Total body-weight reduction at trial endpoint — Foundayo (oral GLP-1) compared with the three FDA-approved injectable GLP-1 weight-loss medications. Sources: ATTAIN-1, STEP-1, SURMOUNT-1, SCALE.[3][7][8][9]

  • Foundayo — orforglipron 17.2 mg (ATTAIN-1, 72 wk)11.1 % TBWL
    first small-molecule oral GLP-1; daily tablet
  • Wegovy — semaglutide 2.4 mg (STEP-1, 68 wk)14.9 % TBWL
  • Zepbound — tirzepatide 15 mg (SURMOUNT-1, 72 wk)20.9 % TBWL
  • Saxenda — liraglutide 3.0 mg (SCALE, 56 wk)8.0 % TBWL
Total body-weight reduction at trial endpoint — Foundayo (oral GLP-1) compared with the three FDA-approved injectable GLP-1 weight-loss medications. Sources: ATTAIN-1, STEP-1, SURMOUNT-1, SCALE.

What does orforglipron cost?

What patients actually pay for Foundayo depends on the access path[4]:

  • Commercial insurance + Foundayo Savings Card: as low as $25 per month for eligible commercially insured patients (not Medicare or Medicaid).
  • Cash pay through LillyDirect: $149 per month for the lowest dose, scaling up at the higher labeled doses (Lilly lists regular prices up to $349 per month for the 14.5 mg and 17.2 mg doses).
  • Medicare Part D: standard Part D does NOT cover Foundayo for the weight management indication. Section 1860D-2(e)(2)(A) of the Social Security Act explicitly excludes agents used for weight loss from Medicare Part D coverage. The current exception is the CMS Medicare GLP-1 Bridge, a time-limited demonstration that runs outside the Part D benefit: from July 1, 2026 through December 31, 2027, eligible Part D enrollees can get Foundayo, Wegovy, or the Zepbound KwikPen for weight loss at a $50 copay.[10] Medicare beneficiaries who do not qualify for the Bridge pay cash for Foundayo for weight management.

For the live provider directory and the channel-by-channel pricing, see our Where to buy Foundayo provider list. To compare cost-per-pound of weight loss across every FDA-approved GLP-1, use our GLP-1 cost-per-pound calculator. You can also browse oral GLP-1 telehealth providers to see which platforms prescribe pill-form options like Foundayo.

How do you pronounce orforglipron?

The standard English pronunciation is or-for-GLI-pron — four syllables, with the stress on the third syllable (GLI). Broken out:

  • or — as in “or”
  • for — as in “for”
  • GLI — as in “glee” (stressed)
  • pron — rhymes with “Ron”

Eli Lilly has not published an official pronunciation guide for orforglipron as of this article's publication date, so this is the standard English reading of the spelling rather than a manufacturer-confirmed pronunciation. The brand name Foundayo is pronounced “foun-DAY-oh” — three syllables, stress on the second.

Frequently Asked Questions

Yes. Orforglipron is the generic (chemical) name and Foundayo is the US brand name. They refer to the same Eli Lilly small-molecule GLP-1 receptor agonist tablet. Both names appear on the FDA-approved label.
The FDA approved Foundayo (orforglipron) on April 1, 2026 to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related medical problem. It is available through LillyDirect and retail pharmacies.
Orforglipron is a once-daily oral tablet. It is the first small-molecule (non-peptide) GLP-1 receptor agonist approved for weight loss. It is not the only weight-loss GLP-1 pill: Wegovy also comes as a once-daily semaglutide tablet, but that tablet must be taken on an empty stomach with a small sip of water and a 30-minute wait, while Foundayo can be taken any time of day with or without food. Zepbound and Saxenda are injections. For the full daily protocol, see our how to take Foundayo guide.
Not on average. At the labeled maximum 17.2 mg dose Foundayo produced about 11.1% mean weight loss over 72 weeks. Wegovy STEP-1 reported about 14.9%, and Zepbound SURMOUNT-1 reported about 20.9% at the 15 mg dose. Foundayo is less effective than the best injectables but is the first small-molecule (non-peptide) oral option.
Adults with obesity, or adults with overweight plus at least one weight-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, or cardiovascular disease. The label itself does not list BMI cutoffs; the ATTAIN-1 trial enrolled adults with a BMI of 30 or higher, or 27 to under 30 with a weight-related condition.
Or-for-GLI-pron — four syllables with the stress on the third syllable (GLI). Lilly has not published an official pronunciation guide, so this is the standard English reading of the spelling.

Related research and tools

Further reading

References

  1. 1.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information (FDA-approved April 1, 2026). Section 2 (dosage), Section 7 (strong CYP3A4 inhibitor 9 mg dose cap), Section 12.3 (half-life 29-49 h), Section 14 (clinical studies, 17.2 mg labeled-dose 72-week results). FDA Approved Labeling. 2026. https://pi.lilly.com/us/foundayo-uspi.pdf
  2. 2.Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Lilly Investor Press Release. 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
  3. 3.Wharton S, Aronne LJ, Garvey WT, Kahan S, Wadden TA, Aroda VR, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  4. 4.Eli Lilly and Company. Foundayo (orforglipron) — patient and product information site. Lilly Foundayo product page. 2026. https://www.foundayo.lilly.com
  5. 5.U.S. National Library of Medicine. FOUNDAYO (orforglipron) tablet — DailyMed label record. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  6. 6.Endocrine News. Pharma Friday: April 3, 2026 — Foundayo approval and rollout coverage. Endocrine Society. 2026. https://endocrinenews.endocrine.org/pharma-friday-april-3-2026
  7. 7.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  8. 8.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  9. 9.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015. PMID: 26132939.
  10. 10.Centers for Medicare & Medicaid Services (CMS). Medicare GLP-1 Bridge: a short-term demonstration giving eligible Part D beneficiaries access to certain GLP-1 drugs for a $50 copay, July 1, 2026 through December 31, 2027. CMS.gov. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
  11. 11.Novo Nordisk Inc. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets — US Prescribing Information (DailyMed). FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

Pricing Compare

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

Pricing Compare

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

Pricing Compare

Get started →